Trafficking of 'immune' CD4+/CD8+ T-lymphocytes into the RENCA tumour microcirculation in vivo in mice

British Journal of Cancer

Volumn 83, Issue 8, 2000, Pages 1061-1068

  Ali, S A ^a   Rees, R C ^a   Anderson, D Q ^a   Reed, M W R ^a   Goepel, J R ^b   Brown, N J ^b  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Immunotherapy; Leucocyte lymphocyte trafficking; Tumour microcirculation

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CREMASTER MUSCLE; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE; HELPER CELL; KIDNEY CARCINOMA; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR BLOOD FLOW;

EID: 0033778291     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1403     Document Type: Article

References (42)

1. Adhesion of tumour-infiltrating lymphocytes to endothelium: A phenotypic and functional analysis
2. The pre-clinical evaluation of 'whole' cell vaccines for prophylaxis and therapy: The use of DISC-HSV vector to transduce cytokine genes
3. Establishment of cell-to-cell contacts by adoptively transferred adherent lymphokine activated killer cells with metastatic melanoma cells
4. Validation of the tumour nodes and metastasis classification of renal cell carcinoma
5. Tumour specific suppressor T cells which inhibit the in vitro generation of cytotoxic T cells from immune and early tumour-bearing host spleens
6. Serum levels of IL-6 as a prognostic factor in metastatic renal cell carcinoma
7. Lymphocyte migration into tissue; the paradigm derived from CD4 subsets
8. Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour conditioned medium
9. Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice
10. + lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene
11. Immunotherapy 1: Cytokine gene transfer strategies
12. Cytokine gene therapy with interleukin 2 transduced fibroblasts: Effect of IL-2 dose on anti-tumour immunity
13. Interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma: An anlysis of 203 consecutively treated patients
14. Tumour necrosis factor induced leucocyte adhesion in normal and tumour vessels: Effect of tumour type, transplantation site and host strain
15. Pretreatment serum markers and lymphocyte response to interleukin therapy
16. Viability and visualisation of fluorescently labelled lymphocytes in vitro and in vivo
17. Interleukin 7 generates antitumour cytotoxic T lymphocytes against routine sarcomas with efficacy in cellular adoptive immunotherapy
18. + T cell clones specific for human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumour expressing the p97 antigen
19. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4, or 5, using modified cDNA expression vectors
20. Requirement for recognition of class II molecules and processed tumour antigen for optimal generation of syngeneic tumour-specific class I restricted CTL
21. Tumour infiltrating lymphocytes and interleukin-2 in the treatment of advanced cancer
22. Sequential contribution of L- and P-selectin to leucocyte rolling in vivo
23. + T-cells during the anti-tumour effects of targeted superantigens
24. IL-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
25. Immunotherapeutic elimination of syngeneic Tumours in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from draining lymph nodes of Tumour bearing mice
26. Analysis of effect of cytokines (interleukins 2, 3, 4, and 6. Granulocyte-Monocyte Colony Stimulating Factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumour
27. Generation of cytotoxic T lymphocytes from peripheral blood
28. Interaction of activated natural killer cells with normal and tumour vessels in cranial windows in mice
29. A murine renal cell carcinoma
30. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
31. Cells and cytokines in immunotherapy and gene therapy of cancer
32. Selective MHC expression in Tumours modulates adaptive and innate antitumour responses
33. Immunotherapy and gene therapy of cancer
34. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2
35. Use of Tumour infiltrating lymphocytes and IL2 in immunotherapy of patients with metastatic melanoma
36. Preferential localisation of human adherent lymphokine-activated killer cells in tumour microcirculation
37. Molecutar mechanisms of immune-mediated lysis of murine renal cancer: Differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells
38. Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2
39. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine activated killer cells
40. Traffic signals for lymphocyte recirculation and leucocyte emigration; the multistep paradigm
41. Experimental and clinical studies of cytokine-gene modified tumour cell
42. Fas-mediated suicide of tumour-reactive T cells following activation by specific tumour: Selective rescue by caspase inhibition